The Relative Bioavailability of a Proposed Phase 2 LY2608204 Test Formulation Compared With the Current Phase 1 LY2608204 Reference Formulation After Administration of a Single Oral 80-mg Dose in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 May 2011
At a glance
- Drugs LY 2608204 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 06 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.